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Abstract
Background: There is a substantial discrepancy between in vitro and in vivo experiments. The
purpose of the present work was development of a theoretical framework to enable improved
prediction of in vivo response from in vitro bioassay results.
Results: For dose-response curve reaches a plateau in vitro we demonstrated that the in vivo
response has only one maximum. For biphasic patterns of biological response in vitro both the
bimodal and biphasic in vivo responses might be observed.
Conclusion: As the main result of this work we have demonstrated that in vivo responses might
be predicted from dose-effect curves measured in vitro.
Background
In vitro bioassay is very useful in biomedical experiments.
It has the potential to yield very important data about
molecular mechanism of action of any biologically active
compounds. However, the major challenge for such
experiments is extrapolation to in vivo responses. Unfortu-
nately, there is a substantial discrepancy between in vitro
and in vivo experiments, and there is a paucity of work
directed to prediction of in vivo response from in vitro bio-
assay. So, the purpose of the present work was develop-
ment of a theoretical framework to enable improved
prediction of in vivo response from in vitro bioassay
results.
Results
A survey of literature revealed that most cases of dose-
effect curves for in vitro experiments fall into three classes.
They are:
• monophasic response;
• biphasic pattern;
• bimodal or polymodal dose-effect curve.
MONOPHASIC RESPONSE is the form most commonly
reported in articles on in vitro bioassay. In these cases, with
increasing dose of biologically active substance (BAS), the
cellular response increases to a maximum (dose-response
curve reaches a plateau). The most general schemes exhib-
iting this class of response can be classified as 3 classes:
(I) BAS regulation of enzyme activity,
(II) Ligand interaction with one type of receptor, and
(III) Ligand interaction with negatively cooperative
receptors.
We will consider these three classes:
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(I): BAS might regulate enzyme activity. It might be:
• substrate:
E+S ←→ ES → E+P → cell response,   (scheme 1)
where E is enzyme, S is substrate, ES is enzyme-substrate
complex, P is product. Cellular response is suggested to be
proportional to product concentration.
Scheme (2) approximates the classic Michaelis scheme
[1].
• enzyme activator (A)
E+S ←→ ES → E+P → cell response
E+A ←→ EA   (scheme 2)
EA+S ←→ EAS → EA+P → cell response increasing,
Scheme (3) is characteristic of many BAS. The majority of
these groups are vitamins and minerals, which are known
to be enzyme cofactors and serve to increase enzyme
activity.
• enzyme inhibitor (I)
E+S ←→ ES → E+P → cell response
E+I ←→ EI → no cell response,   (scheme 3)
For example, there is the large class of drugs, whose action
can be described with the help of scheme (4). This class is
called "inhibitors of angiotensin-converting enzyme".
These drugs are commonly used for hypertension treat-
ment and prevention [2].
(II) Ligand interaction with one type of receptors:
L+R ←→ LR → cell response   (scheme 4)
where L is ligand (BAS), R is receptor, LR is ligand-recep-
tor complex.
Scheme (4) is "classic" receptor theory as described by
Clark (1937) [3].
For example, kinetic schemes of such type were proved in
the case of estrogen regulation of gene expression [4],
apolipoprotein AI, CII, B and E synthesis [5].
(III) Ligand interaction with negative cooperative
receptors
L+R ←→ LR
L+LR ←→ L2R → cell response   (5)
where L2R is complex ligand-receptor complexes.
Scheme (5) is characteristic for insulin receptors [6].
Kinetic equations for schemes (1)–(5) are well known [7].
They include "classic" Michaelis [1] and Clark [3] equa-
tions. It can be shown, due to the first order Taylor series,
equations for the schemes (1)–(4) can be re-formulated
from particle counter theory as:
y = B*x/(1+A*x)   (6)
and for scheme (5):
y = B*x2/(1+A*x2)   (7)
where x is incoming signal (x is BAS concentration). For
scheme (1) x is substrate concentration, for scheme (2) it
is activator concentration, for scheme (3) it is inhibitor
concentration, for schemes (4) and (5) it is ligand concen-
tration. y is cellular response for the in vitro system. A and
B are scaling coefficients.
The BAS concentration in the whole organism changes as
a function of time according to equation (14) (see Meth-
ods.) i.e.
x(t) = C(t) = C0[exp(-kelγt)-exp(-k1t)]   (8)
We used equation (8) as the incoming signal, substituted
this into equations (6) and (7) and solved analytically
using Math Cad 8 graphing software (MathSoft Inc., Cam-
bridge, MA, USA) to predict in vivo responses for mono-
modal in vitro dose-effect curves for schemes (1)–(5). We
used illustrative values from works [8,9] and demon-
strated that for such in vitro dose-effect curves, the in vivo
response has only one maximum (fig. 1).
We define β (degree of conjugation) as the proportion of
BAS that is free of binding proteins and is available to
interact with cognate receptors. The larger is β, the larger
the proportion of "free" BAS (see Methods). For equation
(6) the value of this maximum is increasing as β increases;
for equation (7) this value is maximum for mid-range β
values.
BIPHASIC PATTERNS OF BIOLOGICAL RESPONSE
In this case, in in vitro experiments the low doses of BAS
stimulate cellular response, and the high doses inhibit it.
So, a maximum is observed on the dose-response curve.
The most common kinetic schemes for such response are:Theoretical Biology and Medical Modelling 2005, 2:3 http://www.tbiomed.com/content/2/1/3
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• Negative back loop (substrate and product inhibition):
a) E+S ←→ ES → E+P → cellular response
ES+S ←→ ES2   (9)
b) E+S ←→ ES → E+P → cellular response
ES + P ↔ ESP
Such schemes are characteristic of glucose metabolism [1].
• Presence of two receptor types: one type stimulates cel-
lular response, another type inhibits it.
L+R ←→ LR → "positive" cellular response
L+R' ←→ LR' → "negative" cellular response   (10)
In vivo response for monophasic dose-effect curves measured in vitro Figure 1
In vivo response for monophasic dose-effect curves measured in vitro. B = 1. a) equation (6), b) equation (7). kel = 0.0714 1/min, 
k1 = 0.0277 1/min, C0 = 1 nM, γ = β. Illustrative values for fig. 1, 2, 4 taken from Veldhuis et al., (1993) [8] and similar to those 
measured by Baumann et al., (1987)9 for the clearance of growth hormone (GH).Theoretical Biology and Medical Modelling 2005, 2:3 http://www.tbiomed.com/content/2/1/3
Page 4 of 8
(page number not for citation purposes)
where R are receptors of the first type, R' are receptors of
the second type, LR, LR' are ligand-receptor complexes
with different receptor types.
This mechanism has been proven for estrogen regulation
of nitric oxide synthase (activity in the rat aorta [10]; pro-
tein pS2 expression in hormone-dependent tumors [11]
and so on.
• Desensitization of cellular receptors
L+R ←→ LR → positive cellular response
LR → decrease in receptor number   (11)
It has been suggested, that mechanism (11) is basic for
drug tolerance [7]. For example, this mechanism was
described for uretal cell stimulation by 17-β-estradiol.
Before estradiol treatment, expression of estrogen recep-
tors mRNA in cells was much higher then after 12-days
estradiol administration [12]. It is well known that endog-
enous opioid receptors become down regulated after
chronic exposure to exogenous opioids [13] and receptor
down-regulation has often been observed to follow acute
exposure to hormones including growth hormone [14].
• Change of effector's molecule conformation:
"Active" conformation + ligand suplus ←→ "Passive" confor-
mation   (12)
Scheme (12) was suggested by Bootman and Lipp (1999)
[15] for Ca++ regulation of 1,4,5-trisphosphate activity.
The authors suggested that Ca++ surplus induces a change
in Ca++-channel conformation from "open" or "active" to
"closed" or "passive" [15].
For schemes (9)–(12), due to the first order Taylor series,
this kinetic equation can be derived:
y = A*x*exp(-B*x)   (13)
Using equation (13), we obtained a prediction of in vivo
biphasic dose-effects curves (fig. 2). As is apparent from
the figure, the magnitude and the analytical appearance of
in vivo response is affected by the dose of BAS and its
degree of conjugation (β). Both the bimodal and biphasic
in vivo responses might be observed for biphasic dose-
effect curves. Changes of dose of BAS concentration or its
conjugation with blood proteins (or their concentration)
might dramatically change the form of in vivo response.
For the simulations shown in Figure 2 we used values for
kel and k1 and blood volume (4.9 liters) based on measure-
ments by Baumann et al. (1987) [9] and Veldhuis et al.
(1993) [8] for growth hormone secretion, clearance and
pulsatility. Polymodal biological responses are com-
monly observed in biological systems. It has been demon-
strated, that in some experimental systems,
administration of a single, bolus dose of hormone pro-
duces a polymodal response [16].
Bimodal dose-effect curves are usually observed for BAS
with regulatory activity [17,18]. The mechanism of their
formation is still unclear. From our point of view, bimo-
dal dose-response curve might be described by superposi-
tion of two biphasic dose-effect curves with different B
value. This might be observed in cascade system of signal
transduction and amplification. If x regulate intermediate
z formation in biphasic way with B1, and z has biphasic
response on y formation with B2, then if B1<B2, summary
dose-effect curve (y concentration from x) is bimodal (fig.
3). Differences in B1 and B2 value define the maximum
points. For example, with B2 increasing, the interpeak dis-
tance will also increase.
For systems, which have bimodal dose-effect curve in vitro,
the polymodal response in vivo is observed (fig. 4). The
form of this response might be change to "seems con-
stant" due to BAS concentration of β value. The differences
of maximum values are observed, this differences is time-
dependent: the highest maximum is observed with the
longest observation. It might be demonstrated, that with
change of B2 value to 20, only bimodal in vivo response
will be observed. So, the form and the value of maximums
are dependent from the dose of BAS and degree of
conjugation.
Discussion
Analogues of hormones are commonly used in medicine
for hormone replacement therapy (for example in post-
menopausal women), for oral contraception, as anabolic
drugs, for asthma therapy and so on [2]. But engineered
modifications of hormones, growth factors or their ana-
logs are likely to differ from the native analogues in their
affinity for binding proteins. In view of this, an important
practical consequence of our simulations results are that
the testing of newly designed hormones in in vivo systems
(with endogenous binding proteins) will require meas-
urements of acute biological response at multiple concen-
tration and time points. For longer-term responses
requiring protein synthesis (such as a secretion of body
mass or longitudinal bone growth), it could be argued
that such multiple time point studies would not be as
important. However, in so far as long term biological
responses are the consequence of critical initial events
which may require threshold concentrations of free hor-
mone, or repeated patterns of hormone exposure over
prolonged periods [16,19], this assumption may not be
justified.Theoretical Biology and Medical Modelling 2005, 2:3 http://www.tbiomed.com/content/2/1/3
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Another application of our work may be the study of hor-
mone functions in glandular tumour disorders. With
these disorders, there is usually serious metabolic or hor-
monal dysfunction. From our point of view, it may be not
only due to gland biosynthesis of abnormal hormone.
Tumour-produced hormones may not differ structurally
from their normal analogues. The dysfunctional occurs
due to abnormal concentrations of hormones, which are
synthesised by tumours. As it follows from our results,
changes in concentrations can dramatically change the
form and value of biological response. On the other hand,
in many tumour disorders the concentrations of binding
proteins are changed. For example, in ovarian carcinoma
the changes of sex binding protein and ratio free/bound
sex hormones (β) are observed [20]. As follows from our
results, this can dramatically change the biological
response to such hormones, i.e. apparent biological func-
tions. So with testing in vitro such hormones seems to be
In vivo response for biphasic dose-effect curves measured in vitro Figure 2
In vivo response for biphasic dose-effect curves measured in vitro. B = 1. a) variation of β, C0 = 1 nM, b) variation of C0, β = .388. 
kel = 0.0714 1/min, k1 = 0.0277 1/min, γ = β.Theoretical Biology and Medical Modelling 2005, 2:3 http://www.tbiomed.com/content/2/1/3
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normal (and they may be normal), but in vivo they may
have abnormal effects due to changes of their binding pro-
tein concentration, or ratio free/bound hormone.
Conclusion
So, as a result of this work we have demonstrated that in
vivo responses might be predicted from dose-effect curves
measured in vitro. For monophasic curves, in vivo response
is proportional to BAS concentration. For the most com-
plex  in vitro curves, the value and the form of in vivo
response depends in a predictable way on the dose of BAS
and its degree of conjugation.
Methods
To obtain the discussed results we used linear pharmacok-
inetics model:
where: m1(t) mass of biologically active substance (BAS)
in the place of infusion, m2(t) mass of BAS in compart-
ment (blood), k1,kel constants of hormone diffusion from
place of infusion to blood and excretion form blood
(accordingly).
Many of biologically active substances are conjugate into
complexes with blood proteins (for example: GH, nerves
growth factor, IGF-1):
B+P ⇔K HP   (15)
where B is BAS, P is blood protein, BP is BAS-protein com-
plex, K is dissociation constant.
For many BAS, concentration of free (not bound with
blood proteins) BAS is equal to:
[B] ≈β [B0]   (16)
where β is constant ("degree of conjugation"), [B] is con-
centration of free BAS, [B0] is initial concentration of BAS.
If β = 1 then BAS dose not conjugate with protein. If β = 0
then all BAS is in conjugate form.
It may be that only conjugate BAS (for example,
bilirubin), or only unconjugated BAS can be excreted
form the blood (for example, sex hormones). This means
that for scheme (14) the law of mass action will be written
in the next way:
dm1/dt = -k1m1, m1(0) = M
Possible mechanism of bimodal dose-effect curve formation  for in vitro systems Figure 3
Possible mechanism of bimodal dose-effect curve formation 
for in vitro systems. a) intermediate z formation as function of 
x concentration, B1 = 1, b) final product y formation as func-
tion of z concentration, B2 = 5, c)summary dose-response 
curve. See comments in the text of the article.
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dm2/dt = k1m1 - γkelm2, m2(0) = 0   (17)
where γ is a constant. γ = 1-β if only conjugate form of BAS
can be excreted and γ = β if only unconjugated form is
excreted.
But γ is a constant with respect to t: γ = const(t). This means
that solution of system (17) is:
C(t) = C0[exp(-kelγt)-exp(-k1t)]   (18)
where C(t) is BAS concentration in the blood compart-
ment (C = m2/V, V = const (about 5 liters) is blood vol-
ume), C0 is seems initial BAS concentration (C0 = M/V).
References
1. Lehninger AL, Nelson DL, Cox MM: Principles of biochemistry.
Worth Publish: NY; 1982:1013. 
2. Gilman AG: The pharmacological basis of therapeutics.
McGrawHill: New York, St Louis, San Francisco; 1996:1141. 
3. Clark AJ: General Pharmacology. In Handbuch der Experimentellen
Pharmakologie, supplement 4 Edited by: Heubner W, Schuller J.
Springer Verlag: Berlin; 1937:4-190. 
In vivo response for bimodal dose-effect curves measured in vitro Figure 4
In vivo response for bimodal dose-effect curves measured in vitro. B1 = 1, B2 = 5. a) variation of β, C0 = 1 nM, b) variation of C0, 
β = .388. kel = 0.0714 1/min, k1 = 0.0277 1/min, γ = β.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Theoretical Biology and Medical Modelling 2005, 2:3 http://www.tbiomed.com/content/2/1/3
Page 8 of 8
(page number not for citation purposes)
4. Ponchon M, Lause P, Maiter D: In vitro effects of oestradiol on
galanin gene expression in rat anterior pituitary cells.  J
Neuroendocrinol 2000, 12(6):559-564.
5. Tam SP, Archer TK, Deeley RG: Biphasic effects of estrogen on
apolipoprotein synthesis in human hepatoma cells: mecha-
nism of antagonism by testosterone. Proc Natl Acad Sci USA
1986, 83(10):3111-3115.
6. Alberts B, Dennis B, Lewis J, Raff M, Roberts K, Watson JD: Molec-
ular biology of the cell. Volume 2. Garland publishing Inc: New
York, London; 1989:540. 
7. Varfolomeev SD, Gurevich KG: Biokinetics. Fair-press: Moscow;
1999:720. 
8. Veldhuis JD, Johnson ML, Faunt LM, Mercado M, Baumann G: Influ-
ence of high affinity growth hormone binding protein on
plasma profiles of free and bound GH and on the apparent
half-life of GH. J Clin Invest 1993, 91:629-641.
9. Baumann G, Amburn K, Buchanan TA: The effect of circulating
growth hormone-binding protein on metabolic clearance,
distribution and degradation of human growth hormone. J
Clin Endocrinol Metab 1987, 64:657-660.
10. Binko J, Murphy TV, Majewski H: 17-Beta-estradiol enhances
nitric oxide synthase activity in endothelium-denuded rat
aorta. Clin Exp Pharmacol Physiol 1998, 25(2):120-127.
11. Marsigliante S, Biscozzo L, Leo G, Storelli C: Biphasic Scatchard
plots of oestrogen receptors are associated with low pS2 lev-
els in human breast cancers. Cancer Lett 1999, 144(1):17-23.
12. Meikle A, Forsberg M, Sahlin L, Masironi B, Tasende C, Rodriguez-
Pinon M, Garofalo EG: A biphasic action of estradiol on estro-
gen and progesterone receptor expression in the lamb
uterus. Reprod Nutr Dev 2000, 40(3):283-293.
13. Borgland SL: Acute opioid receptor desensitization and toler-
ance: is there a link?  Clin Exp Pharmacol Physiol 2001,
28(3):147-154.
14. Maiter D, Underwood LE, Maes M, Ketelslegers JM: Acute down-
regulation of the somatogenic receptos in rat liver by a sin-
gle injection of growth hormone.  Endocrinology 1988,
122:1291-1296.
15. Bootman MD, Lipp P: Calcium signaling: ringing changes to the
'bell-shaped curve'. Curr Biol 1999, 9:R876-R878.
16. Nielsen HK, Jorgensen JOL, Brixen K, Moller N, Charles P, Chris-
tensen JS: 24-h Profile of serum osteocalcin in growth hor-
mone (GH) deficient patients with and without GH
treatment. Growth Regulation 1991, 1:153-159.
17. Burlakova EB, Konradov AA, Khudiakov IV: The actions of chemi-
cal agents at ultralow doses on biological objects. Izv Akad
Nauk SSSR (Biol) 1990, 22:184-193.
18. Zaitzev SV, Efanov AM, Sazanov LA: The main regularities and
possible action mechanisms of biologically active substances
in supersmall doses. Russian Chemical J 1999, XLIII:28-33.
19. Isaksson OGP, Jansson J-O, Clark RG, Robinson I: Significance of
the secretory pattern of growth hormone. News in Physiological
Sciences 1986, 1:44-47.
20. Hamilton-Fairley D, White D, Griffiths M, Anyaoku V, Koistinen R,
Seppala M, Franks S: Diurnal variation of sex hormone binding
globulin and insulin-like growth factor binding protein-1 in
women with polycystic ovary syndrome. Clin Endocrinol (Oxf)
1995, 43:159-165.